Drug Profile

Reboxetine - Axsome Therapeutics

Alternative Names: AXS 12

Latest Information Update: 21 Jul 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pfizer
Developer Axsome Therapeutics
Class Antidepressants; Ethers; Morpholines; Sleep disorder therapies; Small molecules
Mechanism of Action Adrenergic uptake inhibitors; Dopamine modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Narcolepsy
New Molecular Entity No

Highest Development Phases

Preregistration Narcolepsy

Most Recent Events

15 Jul 2026 FDA assigns PDUFA action date of (01/05/2027) for reboxetine forNarcolepsy
15 Jul 2026 US FDA accepts NDA for Reboxetine for Narcolepsy (PO)
04 May 2026 Preregistration for Narcolepsy in USA (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com